CNSY
Cerenome, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-38/100
Last price
1.59
▲ 0.03 (1.92%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
1.56
Day high
1.66
Day low
1.55
Volume
69.64K
Market cap
$12.07M
P/E (TTM)
—
52W range
1.49 – 20.25
Trailing performance
Returnvs SPY
1W
-14.52%
-16.5%
1M
-42.39%
-43.5%
3M
-58.38%
-62.9%
6M
-45.55%
-63.7%
YTD
-87.53%
-101.8%
1Y
-91.29%
-107.7%
3Y
-95.25%
-177.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CNSY open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
150.27K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Oct 1, 26 | HAWKINS RICHARD JAMES Director |
— | 921 | — | Direct |
| Oct 1, 26 | HEDRICK MARC HAMILTON Chief Executive Officer |
— | 16.44K | — | Direct |
| Oct 1, 26 | ANDREWS RONALD ASBURY Director |
— | 921 | — | Direct |
| Oct 1, 26 | GUSE KYLE ESQ. Director |
— | 921 | — | Direct |
| Oct 1, 26 | VAN ES-JOHANSSON AN Director |
— | 921 | — | Direct |
| Oct 1, 26 | SIMS ANDREW JOHN HUGH MACINTYRE Chief Financial Officer |
— | 2.98K | — | Direct |
| Oct 1, 26 | CLOWES HOWARD Director |
— | 921 | — | Direct |
| Jul 1, 26 | HAWKINS RICHARD JAMES Director |
— | 922 | — | Direct |
| Jul 1, 26 | HEDRICK MARC HAMILTON Chief Executive Officer |
— | 16.44K | — | Direct |
| Jul 1, 26 | ANDREWS RONALD ASBURY Director |
— | 922 | — | Direct |
| Jul 1, 26 | GUSE KYLE ESQ. Director |
— | 922 | — | Direct |
| Jul 1, 26 | VAN ES-JOHANSSON AN Director |
— | 922 | — | Direct |
| Jul 1, 26 | SIMS ANDREW JOHN HUGH MACINTYRE Chief Financial Officer |
— | 2.98K | — | Direct |
| Jul 1, 26 | CLOWES HOWARD Director |
— | 922 | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ANDREWS RONALD ASBURY |
Director | 1.84K | Conversion of Exercise of derivative security |
CLOWES HOWARD |
Director | 2.90K | Conversion of Exercise of derivative security |
GUSE KYLE ESQ. |
Director | 1.84K | Conversion of Exercise of derivative security |
HAWKINS RICHARD JAMES |
Director | 2.45K | Conversion of Exercise of derivative security |
HEDRICK MARC HAMILTON |
Chief Executive Officer | 60.92K | Conversion of Exercise of derivative security |
LENK ROBERT P |
Director | 139.33K | Purchase |
SIMS ANDREW JOHN HUGH MACINTYRE |
Chief Financial Officer | 12.93K | Conversion of Exercise of derivative security |
VAN ES-JOHANSSON AN |
Director | 1.84K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$12.07M
Enterprise value$3.52M
Revenue (TTM)$4.20M
Gross profit$-8.30M
EBITDA$-25.95M
Net income$-26.09M
EPS (TTM)$-3.46
Free cash flow$-13.97M
Total cash$8.59M
Total debt$44.00K
Book value / share$0.75
Shares outstanding7.59M
Float7.50M
Short % of float8.62%
Dividend yield0.00%
Beta (5Y)1.47
Valuation & profitability ratios
Trailing P/E—
Forward P/E-0.64
PEG ratio2.45
Price / sales—
Price / book2.13
EV / revenue0.84
EV / EBITDA-0.14
Gross margin-197.57%
Operating margin-2203.65%
Profit margin0.00%
Return on equity-614.05%
Return on assets-135.36%
Debt / equity0.81
Current ratio1.37
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $8.38M | $10.58M | $9.69M | $9.70M | -20.8% |
| Selling, general & admin | $12.13M | $9.94M | $8.54M | $10.24M | +22.1% |
| Total operating expense | $15.30M | $14.70M | $13.32M | $19.71M | +4.1% |
| Operating income | -$15.30M | -$14.70M | -$13.32M | -$19.71M | -4.1% |
| Net interest income | -$3.49M | -$3.45M | $5.00K | -$564.00K | -1.2% |
| Pre-tax income | -$22.39M | -$12.98M | -$13.32M | -$20.27M | -72.5% |
| Net income | -$22.39M | -$12.98M | -$13.32M | -$20.27M | -72.5% |
| Net income to common | -$22.39M | -$12.98M | -$13.32M | -$20.27M | -72.5% |
| Basic EPS | -7.25 | -48.75 | -106.00 | -288.75 | +85.1% |
| Diluted EPS | -7.25 | -58.50 | -106.00 | -288.75 | +87.6% |
| EBIT | -$18.78M | -$9.25M | -$12.92M | -$19.56M | -102.9% |
| EBITDA | -$18.33M | -$8.38M | -$12.29M | -$18.95M | -118.7% |
| Basic shares | 3.11M | 265.61K | 125.64K | 70.01K | +1,071.7% |
| Diluted shares | 3.11M | 308.03K | 125.64K | 70.01K | +910.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.26M | $76.00K | $8.55M | $18.12M | — | +5,500.0% |
| Cash & short-term investments | $8.61M | $3.61M | $8.55M | $18.12M | — | +138.8% |
| Total current assets | $15.17M | $5.26M | $9.83M | $21.82M | — | +188.5% |
| Property, plant & equipment | $327.00K | $521.00K | $1.11M | $1.57M | — | -37.2% |
| Goodwill & intangibles | $705.00K | $841.00K | $414.00K | $466.00K | — | -16.2% |
| Total assets | $16.32M | $6.63M | $11.39M | $23.87M | — | +146.1% |
| Total current liabilities | $12.31M | $15.55M | $10.73M | $11.85M | — | -20.8% |
| Current debt | $750.00K | $3.29M | $3.98M | $1.61M | — | -77.2% |
| Long-term debt | — | — | — | $3.79M | $5.00M | — |
| Total debt | $821.00K | $3.37M | $4.18M | $5.64M | — | -75.6% |
| Total liabilities | $12.33M | $15.58M | $12.74M | $17.42M | — | -20.9% |
| Retained earnings | -$515.87M | -$493.48M | -$480.50M | -$467.19M | — | -4.5% |
| Shareholder equity | $4.00M | -$8.95M | -$1.35M | $6.45M | — | +144.7% |
| Working capital | $2.86M | -$10.29M | -$893.00K | $9.96M | — | +127.7% |
| Net tangible assets | $3.29M | -$9.79M | -$1.76M | $5.98M | — | +133.6% |
| Shares issued | 5.56M | 246.19K | 180.91K | 89.60K | — | +2,157.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$22.39M | -$12.98M | -$13.32M | -$20.27M | -72.5% |
| Depreciation & amortisation | $445.00K | $872.00K | $628.00K | $619.00K | -49.0% |
| Stock-based compensation | $1.54M | $550.00K | $569.00K | $606.00K | +180.0% |
| Change in working capital | -$6.04M | $3.22M | -$1.12M | $5.60M | -287.5% |
| Operating cash flow | -$20.77M | -$10.55M | -$12.85M | -$12.97M | -96.8% |
| Capital expenditure | -$67.00K | -$691.00K | -$160.00K | -$759.00K | +90.3% |
| Investing cash flow | -$854.00K | -$4.11M | -$160.00K | -$759.00K | +79.2% |
| Share buybacks | $0 | -$374.00K | -$126.00K | $0 | +100.0% |
| Financing cash flow | $30.31M | $6.19M | $3.44M | $13.45M | +389.9% |
| Free cash flow | -$20.84M | -$11.24M | -$13.01M | -$13.73M | -85.3% |
| End cash position | $8.76M | $76.00K | $8.55M | $18.12M | +11,423.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $4.26M | $2.87M | $2.94M | $2.44M | $1.25M | — | +48.9% |
| Selling, general & admin | $5.20M | $5.28M | $4.17M | $3.44M | $1.68M | — | -1.5% |
| Total operating expense | $9.06M | $7.12M | $5.74M | $4.48M | $1.54M | — | +27.2% |
| Operating income | -$9.06M | -$7.12M | -$5.74M | -$4.48M | -$1.54M | — | -27.2% |
| Net interest income | $51.00K | $173.00K | $29.00K | $59.00K | $177.00K | — | -70.5% |
| Pre-tax income | -$9.01M | -$6.95M | -$5.71M | -$4.42M | $5.15M | — | -29.7% |
| Net income | -$9.01M | -$6.95M | -$5.71M | -$4.42M | $5.15M | — | -29.7% |
| Net income to common | -$9.01M | -$6.95M | -$5.71M | -$4.42M | $5.15M | — | -29.7% |
| Basic EPS | -1.31 | -1.05 | — | -1.00 | 0.62 | -29.86 | -24.8% |
| Diluted EPS | -1.31 | -1.05 | — | -1.00 | 0.62 | -29.86 | -24.8% |
| EBIT | -$9.00M | -$6.93M | -$2.65M | -$4.42M | $5.15M | — | -29.9% |
| EBITDA | -$8.86M | -$6.83M | -$2.56M | -$4.29M | $5.23M | — | -29.7% |
| Basic shares | 6.90M | 6.65M | — | 4.30M | 1.94M | 582.67K | +3.8% |
| Diluted shares | 6.90M | 6.65M | — | 4.30M | 8.37M | 582.67K | +3.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.37M | $3.02M | $4.26M | $13.29M | $2.23M | -21.7% |
| Cash & short-term investments | $8.59M | $15.11M | $8.61M | $16.60M | $6.88M | -43.2% |
| Total current assets | $11.77M | $18.03M | $15.17M | $17.59M | $9.21M | -34.7% |
| Property, plant & equipment | $1.45M | $1.07M | $327.00K | $293.00K | $318.00K | +35.7% |
| Goodwill & intangibles | $637.00K | $671.00K | $705.00K | $746.00K | $773.00K | -5.1% |
| Total assets | $14.03M | $19.92M | $16.32M | $18.67M | $10.35M | -29.6% |
| Total current liabilities | $8.57M | $7.96M | $12.31M | $13.62M | $7.32M | +7.7% |
| Current debt | — | $667.00K | $750.00K | — | — | — |
| Total debt | $44.00K | $725.00K | $821.00K | $21.00K | $30.00K | -93.9% |
| Total liabilities | $8.57M | $7.96M | $12.33M | $13.62M | $7.32M | +7.7% |
| Retained earnings | -$531.82M | -$522.81M | -$515.87M | -$510.15M | -$505.73M | -1.7% |
| Shareholder equity | $5.46M | $11.96M | $4.00M | $5.05M | $3.03M | -54.3% |
| Working capital | $3.20M | $10.07M | $2.86M | $3.97M | $1.90M | -68.2% |
| Net tangible assets | $4.83M | $11.29M | $3.29M | $4.31M | $2.26M | -57.3% |
| Shares issued | 7.31M | 6.87M | 5.56M | 5.27M | 3.70M | +6.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$9.01M | -$6.95M | -$5.71M | -$4.42M | $5.15M | — | -29.7% |
| Depreciation & amortisation | $137.00K | $96.00K | $92.00K | $130.00K | $77.00K | — | +42.7% |
| Stock-based compensation | $830.00K | $1.02M | $713.00K | $527.00K | $152.00K | — | -18.8% |
| Change in working capital | $882.00K | -$419.00K | -$1.36M | $1.26M | -$4.50M | — | +310.5% |
| Operating cash flow | -$7.13M | -$6.24M | -$6.26M | -$2.55M | -$5.80M | — | -14.3% |
| Capital expenditure | -$499.00K | -$818.00K | -$23.00K | -$34.00K | -$7.00K | — | +39.0% |
| Investing cash flow | $5.37M | -$8.53M | -$1.08M | $1.30M | -$4.63M | — | +162.9% |
| Share buybacks | — | — | $0 | $0 | $0 | $0 | — |
| Financing cash flow | $1.11M | $9.04M | $2.80M | $12.31M | $2.80M | — | -87.7% |
| Free cash flow | -$7.63M | -$7.06M | -$6.28M | -$2.58M | -$5.80M | — | -8.1% |
| End cash position | $2.37M | $3.02M | $8.76M | $13.29M | $2.23M | — | -21.7% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.88 | -1.31 | -48.9% |
| Mar 2026 | -0.87 | -1.05 | -20.7% |
| Dec 2025 | -0.92 | 0.00 | +100.0% |
| Sep 2025 | -0.88 | -1.00 | -14.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.03 | 3 | $750.00K | -46.3% |
| Next quarter | -0.97 | 3 | $1.55M | +13.4% |
| Current year | -4.76 | 2 | $3.72M | -28.7% |
| Next year | -2.49 | 4 | $19.14M | +414.6% |
Analyst targets & ownership
Mean target$27.75
High target$43.00
Low target$12.00
Implied upside1645.28%
Analyst count4
ConsensusSTRONG BUY
Strong buy / Buy1 / 3
Hold0
Sell / Strong sell0 / 0
Held by insiders1.98%
Held by institutions15.71%
Institutions holding28
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.81
-12.11% from price
SMA 20
1.98
-19.74% from price
SMA 50
2.80
-43.23% from price
SMA 100
3.81
-58.24% from price
SMA 200
5.69
-72.04% from price
EMA 12
1.84
-13.37% from price
EMA 26
2.17
-26.76% from price
EMA 50
2.70
-41.13% from price
RSI (14)
25.0
Oversold
MACD (12,26,9)
-0.34
Hist 0.00
ATR (14)
0.20
12.53% of price
Realised vol 30D
74.0%
Annualised
Bollinger upper
2.47
20, 2σ
Bollinger lower
1.50
20, 2σ
50 / 200 cross
Death
2.80 vs 5.69
Trend bias
Below 200
-72.04%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.77
More volatile than market
Correlation to SPY
0.23
Largely independent
Realised vol 30D
74.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-93.0%
Peak to trough
Max drawdown 5Y
-99.8%
Peak to trough
ATR 14
0.20
12.53% of price
Beta (reported)
1.47
5Y monthly, from filing
Short interest
Shares short
651.89K
Prior 624.80K
Change vs prior
+4.3%
Shorts adding
% of float
8.62%
Normal
% of shares out
8.59%
Against total outstanding
Days to cover
8.2
Crowded exit
Float
7.50M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 1, 26 | Lake Street | MAINTAINED | Buy | Buy |
| Sep 11, 26 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Jun 8, 26 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Apr 9, 26 | Ascendiant Capital | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:25
Split dateApr 2, 2026
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-10-02
Additional Forms
D · 2026-09-18
Corporate Changes & Voting Matters
8-K · 2026-09-10
Periodic Financial Reports
10-Q · 2026-08-14
Corporate Changes & Voting Matters
8-K · 2026-08-04
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-06-05
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-01-09
Headlines
Cerenome Launches CNSide® CSF Molecular Profile Tests
GlobeNewswire · 1d ago
Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings
GlobeNewswire · 7d ago
Cerenome to Hold CNSide® Business Update Call on September 30, 2026
GlobeNewswire · 12d ago
Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered Lives
GlobeNewswire · 15d ago
Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division
GlobeNewswire · 21d ago
Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment
GlobeNewswire · 27d ago
Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines
GlobeNewswire · 48d ago
Cerenome Reports Second Quarter 2026 Financial Results and Business Update
GlobeNewswire · 54d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.